Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01720-9
Affiliations:
22
Authors:
27
Go to article
Institutions Authors Share
MOE Key Laboratory for Carcinogenesis and Invasion, China
6.000000
 0.22
Zhongshan Hospital, Fudan University, China
4.000000
 0.15
Hengrui, China
3.000000
 0.11
The First Affiliated Hospital of Guangxi Medical University, China
1.000000
 0.04
Peking Union Medical College Hospital (PUMCH), China
1.000000
 0.04
Northern Jiangsu People's Hospital, China
1.000000
 0.04
Qilu Hospital of Shandong University, China
1.000000
 0.04
Tumor Hospital of Guangxi Medical University, China
1.000000
 0.04
Ningbo Medical Center Li Huili Hospital, China
1.000000
 0.04
Mengchao Hepatobiliary Hospital of Fujian Medical University, China
1.000000
 0.04
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China
1.000000
 0.04
The First Affiliated Hospital of Dalian Medical University, China
1.000000
 0.04
Henan Cancer Hospital, ZZU, China
1.000000
 0.04
Fourth Hospital of Hebei Medical University, China
1.000000
 0.04
Eastern Hepatobiliary Surgery Hospital (EHBH), SMMU, China
1.000000
 0.04
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital (SAMSPH), China
1.000000
 0.04
Sichuan Cancer Hospital, China
0.500000
 0.02
University of Electronic Science and Technology of China (UESTC), China
0.500000
 0.02
Interested in Oncology and Carcinogenesis?